Monoclonal antibodies

Bibliography

• Monoclonal Antibodies: Production, Engineering, and Clinical Application. Ritter MA, Ladyman HE (Eds.), Cambridge University Press, Cambridge, UK (1995).
   Google Scholar
• ••This is a complete reference focusing on monoclonal antibodies. It covers informationconcerning their production (by cellular and molecular techniques), purification and structure functional characteristics, together with detailed discussions of their various analytic, diagnostic and therapeutic applications in clinical medicine. Specific clinical areas detailed include: oncology, infectious disease, transplantation, rheumatology, haematology and histopathology.
   Google Scholar
• Antibody therapeutics. Harris WJ, Cunningham C (Eds.), RG Landes Co., Austin, USA (1995).
   Google Scholar
• •Informed discussion about the therapeutic use of conventional and monoclonal antibodies including a summary of results and conclusions from many preclinical and clinical trials. The authors also discuss humanisation techniques.
   Google Scholar
• GODING JVV: Monoclonal Antibodies: Principles and Practice (Edition 3). Academic Press, San Diego, USA (1996).
   Google Scholar
• •This book integrates a discussion of antibody structure and function with detailed methods for monoclonal antibody production, purification, fragmentation, storage and labelling for immunofluorescence and histology. Includes a discussion of consideration for the construction, screening and expression of recombinant antibodies using phage displays.
   Google Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• ••The first description of the discovery and development of principles for production ofmonoclonal antibodies by the hybridoma technique. The authors received the Nobel Prize for carrying this out in 1984.
   Google Scholar
• HARLOW E, LANE DP: Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, USA (1988).
   Google Scholar
• ••A 'hands on' laboratory manual for the production, purification and characterisation ofconvention and monoclonal antibodies.
   Google Scholar
• Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (Eds.), John Wiley & Sons, New York, USA (1992): 2.4.1–2.7.12.
   Google Scholar
• VAUGHAN TJ, OSBOURN JK, TEMPEST PR: Human antibodies by design. Nature Biotechnol. (1998) 16:535–539.
   PubMed Web of Science ®Google Scholar
• •The development of human antimurine antibodies has limited the usefulness of murine monoclonal antibodies. These authors examine the humanisation of monoclonals and discuss the successes with chimerised and humanised monoclonals and the promise of entirely human monoclonal antibodies now being produced from phage display and transgenic mice.
   Google Scholar
• REYNOLDS JC, DEL VECCHIO S, SAKAHARA H, et al.: Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int. J. Radiat. Appl. Instrum.; part B: Nuc. Med.. Biol. (1989) 16:121–125.
   Google Scholar
• KUUS-REICHEL K, GRAUER LS, KARAVODIN LM, KNOTT C, KRUSEMEIER M, KAY NE: Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies Clin. Diagn. Lab. Immunol. (1994) 1:365–372.
   PubMedGoogle Scholar
• GRAZIANO RF, TEMPEST PR, WHITE P, et al.: Construction and characterization of a humanized anti-gamma-immunoglobulin receptor Type I (FcyRI) monoclonal antibody./ Immunol. (1995) 155:4996–5002.
   Web of Science ®Google Scholar
• ORTHO MULTICENTER TRANSPLANT STUDY GROUP: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New Engl. J. Med. (1985) 313:337–342.
   PubMed Web of Science ®Google Scholar
• HOOGENBOOM HR: Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. (1997) 15:62–70.
   PubMed Web of Science ®Google Scholar
• •It is possible to create antibodies binding to any chosen target antigen without animals or hybridomas. In this review, a variety of phage library-based strategies for the isolation of high-affinity antibodies are presented.
   Google Scholar
• BURTON DR, BARBAS CF: Human antibodies from combinatorial libraries. Adv. Immunol. (1994) 57:191–280.
   PubMed Web of Science ®Google Scholar
• FANGER MW, MORGANELLI PM, GUYRE PM: Bispecific antibodies. Crit. Rev. Immunol. (1992) 12:101–124.
   PubMed Web of Science ®Google Scholar
• DRAKEMAN DL, FANGER MW, WALLACE PK: Bispecific antibodies for the treatment of tumours and infectious disease. Exp. Opin. Invest. Drugs (1998) 6:1169–1178.
   Google Scholar
• GOLDSTEIN G: Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc. (1987) 19:1–6.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, KIRKMAN R, LIGHT S, et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New Engl. J. Med. (1998) 338:161–165.
   PubMed Web of Science ®Google Scholar
• NASHAN B, MOORE R, AMLOT P, SCHMIDT AG, ABEYVVICKRAMA K, SOULILLOU JP: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet (1997) 350:1193–1198.
   PubMed Web of Science ®Google Scholar
• WAID TH, THOMPSON JS, MCKEOWN JW, BROWN SA, SEKELA ME: Induction immunotherapy in heart transplantation with T10B9.1A-31: a Phase I study. J. Heart Lung Transplant (1997) 16:913–916.
   PubMed Web of Science ®Google Scholar
• CAVAZZANA-CALVO M, BORDIGONI P, MICHEL G, et al.: A Phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Br. J. Haematol. (1996) 93:131–138.
   PubMed Web of Science ®Google Scholar
• THE EPIC INVESTIGATION: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet (1998) 352:87–92.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New Engl. J. Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• ZHAO ZQ, LEFER DJ, SATO H, HART KK, JEFFORDA PR, VINTEN-JOHANSEN J: Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. J. Leukoc. Biol. (1997) 62:292–300.
   PubMed Web of Science ®Google Scholar
• BEDNAR MM, WRIGHT SD, RAYMOND-RUSSELL SJ, KOHUT JJ, GROSS CE: IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Neurol. Res. (1996) 18:171–175.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Antibodies as cytotoxic therapy. J. Clin. Oncol. (1994) 12:1497–1515.
   PubMed Web of Science ®Google Scholar
• •This review describes the results from trials of unconjugated monoclonal antibodies in the treatment of cancer. The author focuses on trials directed against lymphoma, melanoma, sarcoma, and neuroblastoma. An excellent discussion of how monoclonal antibodies target immune effector mechanisms to the tumour is included.
   Google Scholar
• JURCIC JG, SCHEINBERG DA, HOUGHTON AN: Monoclonal antibody therapy of cancer.>Cancer Chemother. Biol. Response Modif (1997) 17:195–216.
   PubMedGoogle Scholar
• •Status report on the use of monoclonal antibodies for the diagnosis and therapy of cancer. The authors review the various tumour associated antigens defined as targets for monoclonal antibodies and then examine the preclinical and clinical use of selected monoclonal antibodies. Future prospects for monoclonal antibodies are also covered.
   Google Scholar
• PEGRAM MD, LIPTON A, HAYES DF, et al.: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. (1998) 16:2659–2671.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
   PubMed Web of Science ®Google Scholar
• BERCHUCK A, KAMEL A, WHITAKER R, et al.: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. (1990) 50:4087–4091.
   PubMed Web of Science ®Google Scholar
• STUMM G, EBERWEIN S, ROSTOCK-WOLF S, et al.: Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J. Cancer (1996) 69:17–22.
   PubMed Web of Science ®Google Scholar
• CARUSO ML, VALENTINI AM: Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res. (1996) 16:3813–3818.
   PubMed Web of Science ®Google Scholar
• VALONE FH, KAUFMAN PA, GUYRE PM, et al.: Phase Ia/Ib trial of bispecific antibody MDX210 (anti-HER-2/neu x anti-FcyRI) in patients with advanced breast or ovarian cancer that over-expresses the proto-oncogene HER-2/neu. J. Clin. Oncol. (1995) 13:2281–2292.
   PubMed Web of Science ®Google Scholar
• WEINER LM, CLARK JI, DAVEY M, et al.: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. (1995) 55:4586–4593.
   PubMed Web of Science ®Google Scholar
• Protein Engineering of Antibody Molecules for Prophylaxis and Therapeutic Applications in Man. Clark M (Ed.), Academic Press, San Diego, USA (1993) 171–177.
   Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA, et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, SMITH B, APPELBAUM FR: The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood (1996) 88:637a.
   Google Scholar
• MCLAUGHLIN P, CABANILLAS F, GRILLO-LOPEZ AJ, et al.: IDEC-C2B8 anti-CD20 antibody: final report on a Phase III pivotal trial in patients (PTS) with relapsed low-grade or follicular lymphoma (LF/F NHL). Blood (1996) 88\(Suppl. 1):90a.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR, et al.: Radioimmunotherapy of B-cell lymphoma with [1311]anti-B1 (anti-CD20) antibody. New Engl. J. Med. (1993) 329:459–465.
   PubMed Web of Science ®Google Scholar
• LIU SY, EARY JF, PETERSDORF SH, et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol. (1998) 16:3270–3278.
   PubMed Web of Science ®Google Scholar
• PRESS OW: Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer J. Sci. Am. (1998) 2:S19–26.
   Google Scholar
• VITETTA ES, STONE M, AMLOT P, et al.: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. (1991) 51:4052–4058.
   PubMed Web of Science ®Google Scholar
• MATTHEWS DC: Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia (1998) 1:S33–36.
   Google Scholar
• SIEVERS EL, BERNSTEIN ID, SPIELBERGER RT: Dose escalation Phase I study of recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate (CMA-676) in patients with relapsed or refractory acute myeloid leukemia. Proc. Ann. Meet. Am. Assoc. Cancer (1997) 16:A8.
   Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl. J. Med. (1997) 337:1029–1035.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• JOHNSON S, OLIVER C, PRINCE GA, et al.: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. (1997) 176:1215–1224.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-RSV STUDY GROUP: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102:531–537.
   PubMed Web of Science ®Google Scholar
• LONBERG N, TAYLOR LD, HARDING FA, et al.: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 368:856–859.
   PubMed Web of Science ®Google Scholar
• •The authors discuss the development of a transgenic mouse that expresses human IgM, IgG and Igic in the absence of mouse IgM or Igic. When immunised, these mice produce hybridomas secreting human IgGic antigen-specific antibodies. The specific advantages to this system are the mice are easy to immunise, are not tolerant to most human antigens, and their B-cells form stable hybridoma cell lines.
   Google Scholar
• FISHWILD DM, O'DONNELL SL, BENGOECHEA T, et al.: High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnol. (1996) 14:845–851.
   PubMed Web of Science ®Google Scholar